Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Trial Profile

Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2018

At a glance

  • Drugs AL 101 (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma; T cell lymphoma
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 29 May 2018 Status changed from active, no longer recruiting to completed.
    • 30 Jan 2018 Planned End Date changed from 29 Jun 2018 to 1 Jul 2018.
    • 30 Jan 2018 Planned primary completion date changed from 29 Jun 2018 to 28 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top